Subscribe to Newsletter to get latest insights & analysis in your inbox. Download the ETPharma App and get the Realtime updates and Save your favourite articles. By Ludwig ​BurgerFRANKFURT, - The two co-founders and leading executives of Germany's BioNTech will leave the COVID-19 vaccine maker by the end of 2026 to start again with a new company, the biotech firm said on Tuesday. BioNTech said ​its current drug development pipeline, including cancer therapies and the COVID-19 vaccine ⁠franchise, would be unaffected by the founders' plans to strike out ​on their own. ($1 = 0.8593 euros) (Reporting by Ludwig Burger, Editing by Linda Pasquini and Louise Heavens)>

Source: Economic Times March 11, 2026 02:56 UTC